Scynexis Inc - Company & Market Research Reports

SCYNEXIS is a drug development company that develops and commercializes anti-infectives to address unmet therapeutic needs. Its lead product candidate, SCY-078, is a novel and structurally distinct triterpenoid glucan synthase inhibitor. SCY-078 is in Phase 2 clinical development as an oral and intravenous drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. Founded in 1999, the company is headquartered in Jersey City, New Jersey.

From
Hepatitis B - Pipeline Review, H1 2018 - Product Thumbnail Image

Hepatitis B - Pipeline Review, H1 2018

  • Drug Pipelines
  • 365 Pages
From
Mycoses Global Clinical Trials Review, H1, 2018 - Product Thumbnail Image

Mycoses Global Clinical Trials Review, H1, 2018

  • Clinical Trials
  • 492 Pages
From
From
From
From
From
Aspergillosis - Pipeline Review, H2 2018 - Product Thumbnail Image

Aspergillosis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 140 Pages
From
Candidiasis - Pipeline Review, H2 2018 - Product Thumbnail Image

Candidiasis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 162 Pages
From
From
From
Candidiasis - Pipeline Review, H1 2018 - Product Thumbnail Image

Candidiasis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 172 Pages
From
Aspergillosis - Pipeline Review, H1 2018 - Product Thumbnail Image

Aspergillosis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 128 Pages
From
From
From
Loading Indicator
adroll